Docetaxel Injection
Product Images NDC 43066-046

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 43066-046). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Docetaxel-figure-1 (Docetaxel Figure 1)

A Kaplan-Meier curve chart showing disease-free survival probability (%) over time in months, comparing two treatment groups labeled TAC and FAC. The chart displays a gradual decline in survival probability for both groups over a period of 0 to 66 months.*

FDA Label Image

Docetaxel-figure-10 (Docetaxel Figure 10)

A Kaplan-Meier survival curve titled 'Figure 10 - TAX324 Overall Survival K-M Curve' comparing survival probabilities over time in months between two groups, TPF and PF, with patient numbers at risk listed below the x-axis. The y-axis represents survival probability in percentage from 0 to 100.*

FDA Label Image

Docetaxel-figure-2 (Docetaxel Figure 2)

A Kaplan-Meier survival curve chart titled 'Figure 2 - TAX316 Overall Survival K-M Curve' showing survival probability percentage on the y-axis and survival time in months on the x-axis. The graph compares overall survival between two groups labeled TAC and FAC over a period exceeding 66 months.*

FDA Label Image

Docetaxel-figure-3 (Docetaxel Figure 3)

A Kaplan-Meier survival curve chart comparing overall survival probabilities over time (in months) between Docetaxel 75 mg/m² treatment and Best Supportive Care (BSC). The chart shows cumulative survival probability on the y-axis and survival time in months on the x-axis, with a statistical significance note (log-rank p = 0.010).*

FDA Label Image

Docetaxel-figure-4 (Docetaxel Figure 4)

A Kaplan-Meier survival curve graph titled 'Figure 4 - TAX320 Survival K-M Curves - Docetaxel 75 mg/m² vs. Vinorelbine or Ifosfamide Control.' The graph displays cumulative survival probability over time in months, comparing two groups labeled T75 and V/I with corresponding solid and dashed lines. The plot includes overall survival with a log-rank p-value of 0.13.*

FDA Label Image

Docetaxel-figure-5 (Docetaxel Figure 5)

A Kaplan-Meier survival curve chart titled 'Figure 5 - TAX327 Survival K-M Curves' comparing survival probabilities over 30 months. Two curves represent different treatment groups labeled T75 q3w and M q3w, with survival probability on the y-axis and survival time in months on the x-axis.*

FDA Label Image

Docetaxel-figure-6 (Docetaxel Figure 6)

A Kaplan-Meier curve chart titled 'Gastric Cancer Study (TAX325) Time to Progression K-M Cu' showing probability (%) on the y-axis versus time in months on the x-axis. Two lines represent different treatment groups, labeled TCF and CF, depicting the progression probability over a 24-month period.*

FDA Label Image

Docetaxel-figure-7 (Docetaxel Figure 7)

Kaplan-Meier survival curve from a gastric cancer study (TAX325) showing survival probability (%) over survival time in months. Two treatment groups are compared: TCF and CF, with their respective survival trajectories plotted.*

FDA Label Image

Docetaxel-figure-8 (Docetaxel Figure 8)

A Kaplan-Meier curve depicting progression-free survival probability (%) over time in months for two groups labeled TPF and PF. The graph shows survival trends from 0 to 42 months, with TPF having higher progression-free survival throughout compared to PF.*

FDA Label Image

Docetaxel-figure-9 (Docetaxel Figure 9)

A Kaplan-Meier overall survival curve graph from the TAX323 study depicting survival probability (%) over survival time in months. The graph shows two lines comparing TPF versus PF treatment groups, with survival probability decreasing over time up to 72 months.*

FDA Label Image

Docetaxel-structure (Docetaxel Structure)

Chemical structure of the active ingredient docetaxel, showing its complex molecular arrangement with multiple rings, hydroxyl groups, and ester linkages.*

FDA Label Image

Image-01 (Image 01)

Label for Docetaxel Injection, USP 20 mg/2 mL (10 mg/mL) intravenous injection, single-dose vial. It is labeled for intravenous use only, to be added to infusion solution with concentration check before preparation. The label includes caution for cytotoxicity and storage instructions at 20° to 25°C. Manufactured for Baxter Healthcare Corporation.*

FDA Label Image

Image-02 (Image 02)

Carton label for Docetaxel Injection, USP 20 mg/2 mL (10 mg/mL) single-dose vial for intravenous use, manufactured by Alembic Pharmaceuticals Limited and labeled by Baxter Healthcare Corporation. The label includes warnings about cytotoxicity and instructions to add to infusion solution, with storage conditions and concentration check reminders.*

FDA Label Image

Image-03 (Image 03)

Label for Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) intravenous injection in an 8 mL multiple-dose vial, manufactured by Baxter Healthcare Corporation. The label includes concentration warnings, storage instructions, and manufacturing details, indicating it is sterile and for prescription use only.*

FDA Label Image

Image-04 (Image 04)

Label for Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) multiple-dose vial for intravenous use by Baxter Healthcare Corporation. The label states the product is ready to add to infusion solution and highlights caution as a cytotoxic agent. It includes storage instructions, formulation details, NDC 43066-046-08, and manufacturer information for Alembic Pharmaceuticals Limited.*

FDA Label Image

Image-05 (Image 05)

Label for Docetaxel Injection, USP 160 mg/16 mL (10 mg/mL) intravenous injection, sterile, in a 16 mL multiple-dose vial. Manufactured by Baxter Healthcare Corporation, this label includes storage instructions, active ingredient concentration, and warnings about cytotoxicity. The label also specifies preparation instructions and includes a barcode.*

FDA Label Image

Image-06 (Image 06)

Packaging label for Docetaxel Injection, USP 160 mg/16 mL (10 mg/mL) intravenous injection. It is a multiple-dose vial supplied in a 16 mL volume. The label shows the product is ready to add to infusion solution, manufactured by Alembic Pharmaceuticals Limited for Baxter Healthcare Corporation. It includes storage instructions, a caution that it is a cytotoxic agent, and a barcode with NDC 43066-048-16.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.